aluates Reports

$ 0.0

Automative

Global Wet Macular Degeneration Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-11E8605

Global Wet Macular Degeneration Market Insights Forecast to 2028

BUY CHAPTERS

Global Wet Macular Degeneration Market Research Report 2025

Code: QYRE-Auto-11E8605

Report

July 2025

Pages:85

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Pfizer Inc

F. Hoffmann-La Roche AG

Regeneron Pharmaceuticals Inc

Novartis

Bausch Health Companies Inc.

Apellis Pharmaceuticals Inc

GlaxoSmithKline PLC

Ophthotech Corporation

Gilead Sciences Inc

Alcon

Genzyme Corporation

Boehringer Ingelheim GmbH

Eyegate Pharmaceuticals Inc.

EyeCyte, Inc.

PanOptica Inc

Wet Macular Degeneration Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Wet Macular Degeneration Market

The global market for Wet Macular Degeneration was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Wet macular degeneration is a chronic eye disorder that induces vague vision or a blind spot in the patient"s visual field.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Wet Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wet Macular Degeneration.

The Wet Macular Degeneration market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Wet Macular Degeneration market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Wet Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Wet Macular Degeneration Market Report

Report Metric	Details
Report Name	Wet Macular Degeneration Market
CAGR	5%
Segment by Type	by Drug by Route of Administration
Segment by Application	Hospitals Clinics Research Institutes Academic Institutes
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer Inc., F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Novartis AG, Bausch Health Companies Inc., Apellis Pharmaceuticals Inc., GlaxoSmithKline plc, Ophthotech Corporation, Gilead Sciences, Inc., Alcon, Genzyme Corporation, Boehringer Ingelheim GmbH, EyeGate Pharmaceuticals, Inc., EyeCyte, Inc., PanOptica Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Wet Macular Degeneration company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Wet Macular Degeneration Market report?

Ans: The main players in the Wet Macular Degeneration Market are Pfizer Inc., F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Novartis AG, Bausch Health Companies Inc., Apellis Pharmaceuticals Inc., GlaxoSmithKline plc, Ophthotech Corporation, Gilead Sciences, Inc., Alcon, Genzyme Corporation, Boehringer Ingelheim GmbH, EyeGate Pharmaceuticals, Inc., EyeCyte, Inc., PanOptica Inc

What are the Application segmentation covered in the Wet Macular Degeneration Market report?

Ans: The Applications covered in the Wet Macular Degeneration Market report are Hospitals, Clinics, Research Institutes, Academic Institutes

What are the Type segmentation covered in the Wet Macular Degeneration Market report?

Ans: The Types covered in the Wet Macular Degeneration Market report are by Drug, by Route of Administration

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Wet Macular Degeneration Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 by Drug

1.2.3 by Route of Administration

1.3 Market by Application

1.3.1 Global Wet Macular Degeneration Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Research Institutes

1.3.5 Academic Institutes

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Wet Macular Degeneration Market Perspective (2020-2031)

2.2 Global Wet Macular Degeneration Growth Trends by Region

2.2.1 Global Wet Macular Degeneration Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Wet Macular Degeneration Historic Market Size by Region (2020-2025)

2.2.3 Wet Macular Degeneration Forecasted Market Size by Region (2026-2031)

2.3 Wet Macular Degeneration Market Dynamics

2.3.1 Wet Macular Degeneration Industry Trends

2.3.2 Wet Macular Degeneration Market Drivers

2.3.3 Wet Macular Degeneration Market Challenges

2.3.4 Wet Macular Degeneration Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Wet Macular Degeneration Players by Revenue

3.1.1 Global Top Wet Macular Degeneration Players by Revenue (2020-2025)

3.1.2 Global Wet Macular Degeneration Revenue Market Share by Players (2020-2025)

3.2 Global Wet Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Wet Macular Degeneration Revenue

3.4 Global Wet Macular Degeneration Market Concentration Ratio

3.4.1 Global Wet Macular Degeneration Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Wet Macular Degeneration Revenue in 2024

3.5 Global Key Players of Wet Macular Degeneration Head office and Area Served

3.6 Global Key Players of Wet Macular Degeneration, Product and Application

3.7 Global Key Players of Wet Macular Degeneration, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Wet Macular Degeneration Breakdown Data by Type

4.1 Global Wet Macular Degeneration Historic Market Size by Type (2020-2025)

4.2 Global Wet Macular Degeneration Forecasted Market Size by Type (2026-2031)

5 Wet Macular Degeneration Breakdown Data by Application

5.1 Global Wet Macular Degeneration Historic Market Size by Application (2020-2025)

5.2 Global Wet Macular Degeneration Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Wet Macular Degeneration Market Size (2020-2031)

6.2 North America Wet Macular Degeneration Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Wet Macular Degeneration Market Size by Country (2020-2025)

6.4 North America Wet Macular Degeneration Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Wet Macular Degeneration Market Size (2020-2031)

7.2 Europe Wet Macular Degeneration Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Wet Macular Degeneration Market Size by Country (2020-2025)

7.4 Europe Wet Macular Degeneration Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Wet Macular Degeneration Market Size (2020-2031)

8.2 Asia-Pacific Wet Macular Degeneration Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Wet Macular Degeneration Market Size by Region (2020-2025)

8.4 Asia-Pacific Wet Macular Degeneration Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Wet Macular Degeneration Market Size (2020-2031)

9.2 Latin America Wet Macular Degeneration Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Wet Macular Degeneration Market Size by Country (2020-2025)

9.4 Latin America Wet Macular Degeneration Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Wet Macular Degeneration Market Size (2020-2031)

10.2 Middle East & Africa Wet Macular Degeneration Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Wet Macular Degeneration Market Size by Country (2020-2025)

10.4 Middle East & Africa Wet Macular Degeneration Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer Inc.

11.1.1 Pfizer Inc. Company Details

11.1.2 Pfizer Inc. Business Overview

11.1.3 Pfizer Inc. Wet Macular Degeneration Introduction

11.1.4 Pfizer Inc. Revenue in Wet Macular Degeneration Business (2020-2025)

11.1.5 Pfizer Inc. Recent Development

11.2 F. Hoffmann-La Roche AG

11.2.1 F. Hoffmann-La Roche AG Company Details

11.2.2 F. Hoffmann-La Roche AG Business Overview

11.2.3 F. Hoffmann-La Roche AG Wet Macular Degeneration Introduction

11.2.4 F. Hoffmann-La Roche AG Revenue in Wet Macular Degeneration Business (2020-2025)

11.2.5 F. Hoffmann-La Roche AG Recent Development

11.3 Regeneron Pharmaceuticals, Inc.

11.3.1 Regeneron Pharmaceuticals, Inc. Company Details

11.3.2 Regeneron Pharmaceuticals, Inc. Business Overview

11.3.3 Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Introduction

11.3.4 Regeneron Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2020-2025)

11.3.5 Regeneron Pharmaceuticals, Inc. Recent Development

11.4 Novartis AG

11.4.1 Novartis AG Company Details

11.4.2 Novartis AG Business Overview

11.4.3 Novartis AG Wet Macular Degeneration Introduction

11.4.4 Novartis AG Revenue in Wet Macular Degeneration Business (2020-2025)

11.4.5 Novartis AG Recent Development

11.5 Bausch Health Companies Inc.

11.5.1 Bausch Health Companies Inc. Company Details

11.5.2 Bausch Health Companies Inc. Business Overview

11.5.3 Bausch Health Companies Inc. Wet Macular Degeneration Introduction

11.5.4 Bausch Health Companies Inc. Revenue in Wet Macular Degeneration Business (2020-2025)

11.5.5 Bausch Health Companies Inc. Recent Development

11.6 Apellis Pharmaceuticals Inc.

11.6.1 Apellis Pharmaceuticals Inc. Company Details

11.6.2 Apellis Pharmaceuticals Inc. Business Overview

11.6.3 Apellis Pharmaceuticals Inc. Wet Macular Degeneration Introduction

11.6.4 Apellis Pharmaceuticals Inc. Revenue in Wet Macular Degeneration Business (2020-2025)

11.6.5 Apellis Pharmaceuticals Inc. Recent Development

11.7 GlaxoSmithKline plc

11.7.1 GlaxoSmithKline plc Company Details

11.7.2 GlaxoSmithKline plc Business Overview

11.7.3 GlaxoSmithKline plc Wet Macular Degeneration Introduction

11.7.4 GlaxoSmithKline plc Revenue in Wet Macular Degeneration Business (2020-2025)

11.7.5 GlaxoSmithKline plc Recent Development

11.8 Ophthotech Corporation

11.8.1 Ophthotech Corporation Company Details

11.8.2 Ophthotech Corporation Business Overview

11.8.3 Ophthotech Corporation Wet Macular Degeneration Introduction

11.8.4 Ophthotech Corporation Revenue in Wet Macular Degeneration Business (2020-2025)

11.8.5 Ophthotech Corporation Recent Development

11.9 Gilead Sciences, Inc.

11.9.1 Gilead Sciences, Inc. Company Details

11.9.2 Gilead Sciences, Inc. Business Overview

11.9.3 Gilead Sciences, Inc. Wet Macular Degeneration Introduction

11.9.4 Gilead Sciences, Inc. Revenue in Wet Macular Degeneration Business (2020-2025)

11.9.5 Gilead Sciences, Inc. Recent Development

11.10 Alcon

11.10.1 Alcon Company Details

11.10.2 Alcon Business Overview

11.10.3 Alcon Wet Macular Degeneration Introduction

11.10.4 Alcon Revenue in Wet Macular Degeneration Business (2020-2025)

11.10.5 Alcon Recent Development

11.11 Genzyme Corporation

11.11.1 Genzyme Corporation Company Details

11.11.2 Genzyme Corporation Business Overview

11.11.3 Genzyme Corporation Wet Macular Degeneration Introduction

11.11.4 Genzyme Corporation Revenue in Wet Macular Degeneration Business (2020-2025)

11.11.5 Genzyme Corporation Recent Development

11.12 Boehringer Ingelheim GmbH

11.12.1 Boehringer Ingelheim GmbH Company Details

11.12.2 Boehringer Ingelheim GmbH Business Overview

11.12.3 Boehringer Ingelheim GmbH Wet Macular Degeneration Introduction

11.12.4 Boehringer Ingelheim GmbH Revenue in Wet Macular Degeneration Business (2020-2025)

11.12.5 Boehringer Ingelheim GmbH Recent Development

11.13 EyeGate Pharmaceuticals, Inc.

11.13.1 EyeGate Pharmaceuticals, Inc. Company Details

11.13.2 EyeGate Pharmaceuticals, Inc. Business Overview

11.13.3 EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Introduction

11.13.4 EyeGate Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2020-2025)

11.13.5 EyeGate Pharmaceuticals, Inc. Recent Development

11.14 EyeCyte, Inc.

11.14.1 EyeCyte, Inc. Company Details

11.14.2 EyeCyte, Inc. Business Overview

11.14.3 EyeCyte, Inc. Wet Macular Degeneration Introduction

11.14.4 EyeCyte, Inc. Revenue in Wet Macular Degeneration Business (2020-2025)

11.14.5 EyeCyte, Inc. Recent Development

11.15 PanOptica Inc

11.15.1 PanOptica Inc Company Details

11.15.2 PanOptica Inc Business Overview

11.15.3 PanOptica Inc Wet Macular Degeneration Introduction

11.15.4 PanOptica Inc Revenue in Wet Macular Degeneration Business (2020-2025)

11.15.5 PanOptica Inc Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

F. Hoffmann-La Roche AG

Regeneron Pharmaceuticals Inc

Novartis

Bausch Health Companies Inc.

Apellis Pharmaceuticals Inc

GlaxoSmithKline PLC

Ophthotech Corporation

Gilead Sciences Inc

Alcon

Genzyme Corporation

Boehringer Ingelheim GmbH

Eyegate Pharmaceuticals Inc.

EyeCyte, Inc.

PanOptica Inc

List of Tables

Table 1. Global Wet Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of by Drug

Table 3. Key Players of by Route of Administration

Table 4. Global Wet Macular Degeneration Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Wet Macular Degeneration Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Wet Macular Degeneration Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Wet Macular Degeneration Market Share by Region (2020-2025)

Table 8. Global Wet Macular Degeneration Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Wet Macular Degeneration Market Share by Region (2026-2031)

Table 10. Wet Macular Degeneration Market Trends

Table 11. Wet Macular Degeneration Market Drivers

Table 12. Wet Macular Degeneration Market Challenges

Table 13. Wet Macular Degeneration Market Restraints

Table 14. Global Wet Macular Degeneration Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Wet Macular Degeneration Market Share by Players (2020-2025)

Table 16. Global Top Wet Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Macular Degeneration as of 2024)

Table 17. Ranking of Global Top Wet Macular Degeneration Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Wet Macular Degeneration Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Wet Macular Degeneration, Headquarters and Area Served

Table 20. Global Key Players of Wet Macular Degeneration, Product and Application

Table 21. Global Key Players of Wet Macular Degeneration, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Wet Macular Degeneration Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Wet Macular Degeneration Revenue Market Share by Type (2020-2025)

Table 25. Global Wet Macular Degeneration Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Wet Macular Degeneration Revenue Market Share by Type (2026-2031)

Table 27. Global Wet Macular Degeneration Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Wet Macular Degeneration Revenue Market Share by Application (2020-2025)

Table 29. Global Wet Macular Degeneration Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Wet Macular Degeneration Revenue Market Share by Application (2026-2031)

Table 31. North America Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Wet Macular Degeneration Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Wet Macular Degeneration Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Wet Macular Degeneration Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Wet Macular Degeneration Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Wet Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Wet Macular Degeneration Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Wet Macular Degeneration Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Wet Macular Degeneration Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Wet Macular Degeneration Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Wet Macular Degeneration Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Wet Macular Degeneration Market Size by Country (2026-2031) & (US$ Million)

Table 46. Pfizer Inc. Company Details

Table 47. Pfizer Inc. Business Overview

Table 48. Pfizer Inc. Wet Macular Degeneration Product

Table 49. Pfizer Inc. Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 50. Pfizer Inc. Recent Development

Table 51. F. Hoffmann-La Roche AG Company Details

Table 52. F. Hoffmann-La Roche AG Business Overview

Table 53. F. Hoffmann-La Roche AG Wet Macular Degeneration Product

Table 54. F. Hoffmann-La Roche AG Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 55. F. Hoffmann-La Roche AG Recent Development

Table 56. Regeneron Pharmaceuticals, Inc. Company Details

Table 57. Regeneron Pharmaceuticals, Inc. Business Overview

Table 58. Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Product

Table 59. Regeneron Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 60. Regeneron Pharmaceuticals, Inc. Recent Development

Table 61. Novartis AG Company Details

Table 62. Novartis AG Business Overview

Table 63. Novartis AG Wet Macular Degeneration Product

Table 64. Novartis AG Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 65. Novartis AG Recent Development

Table 66. Bausch Health Companies Inc. Company Details

Table 67. Bausch Health Companies Inc. Business Overview

Table 68. Bausch Health Companies Inc. Wet Macular Degeneration Product

Table 69. Bausch Health Companies Inc. Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 70. Bausch Health Companies Inc. Recent Development

Table 71. Apellis Pharmaceuticals Inc. Company Details

Table 72. Apellis Pharmaceuticals Inc. Business Overview

Table 73. Apellis Pharmaceuticals Inc. Wet Macular Degeneration Product

Table 74. Apellis Pharmaceuticals Inc. Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 75. Apellis Pharmaceuticals Inc. Recent Development

Table 76. GlaxoSmithKline plc Company Details

Table 77. GlaxoSmithKline plc Business Overview

Table 78. GlaxoSmithKline plc Wet Macular Degeneration Product

Table 79. GlaxoSmithKline plc Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 80. GlaxoSmithKline plc Recent Development

Table 81. Ophthotech Corporation Company Details

Table 82. Ophthotech Corporation Business Overview

Table 83. Ophthotech Corporation Wet Macular Degeneration Product

Table 84. Ophthotech Corporation Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 85. Ophthotech Corporation Recent Development

Table 86. Gilead Sciences, Inc. Company Details

Table 87. Gilead Sciences, Inc. Business Overview

Table 88. Gilead Sciences, Inc. Wet Macular Degeneration Product

Table 89. Gilead Sciences, Inc. Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 90. Gilead Sciences, Inc. Recent Development

Table 91. Alcon Company Details

Table 92. Alcon Business Overview

Table 93. Alcon Wet Macular Degeneration Product

Table 94. Alcon Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 95. Alcon Recent Development

Table 96. Genzyme Corporation Company Details

Table 97. Genzyme Corporation Business Overview

Table 98. Genzyme Corporation Wet Macular Degeneration Product

Table 99. Genzyme Corporation Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 100. Genzyme Corporation Recent Development

Table 101. Boehringer Ingelheim GmbH Company Details

Table 102. Boehringer Ingelheim GmbH Business Overview

Table 103. Boehringer Ingelheim GmbH Wet Macular Degeneration Product

Table 104. Boehringer Ingelheim GmbH Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 105. Boehringer Ingelheim GmbH Recent Development

Table 106. EyeGate Pharmaceuticals, Inc. Company Details

Table 107. EyeGate Pharmaceuticals, Inc. Business Overview

Table 108. EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Product

Table 109. EyeGate Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 110. EyeGate Pharmaceuticals, Inc. Recent Development

Table 111. EyeCyte, Inc. Company Details

Table 112. EyeCyte, Inc. Business Overview

Table 113. EyeCyte, Inc. Wet Macular Degeneration Product

Table 114. EyeCyte, Inc. Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 115. EyeCyte, Inc. Recent Development

Table 116. PanOptica Inc Company Details

Table 117. PanOptica Inc Business Overview

Table 118. PanOptica Inc Wet Macular Degeneration Product

Table 119. PanOptica Inc Revenue in Wet Macular Degeneration Business (2020-2025) & (US$ Million)

Table 120. PanOptica Inc Recent Development

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

Table 124. Authors List of This Report

List of Figures

Figure 1. Wet Macular Degeneration Picture

Figure 2. Global Wet Macular Degeneration Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Wet Macular Degeneration Market Share by Type: 2024 VS 2031

Figure 4. by Drug Features

Figure 5. by Route of Administration Features

Figure 6. Global Wet Macular Degeneration Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Wet Macular Degeneration Market Share by Application: 2024 VS 2031

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Research Institutes Case Studies

Figure 11. Academic Institutes Case Studies

Figure 12. Wet Macular Degeneration Report Years Considered

Figure 13. Global Wet Macular Degeneration Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Wet Macular Degeneration Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Wet Macular Degeneration Market Share by Region: 2024 VS 2031

Figure 16. Global Wet Macular Degeneration Market Share by Players in 2024

Figure 17. Global Top Wet Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Macular Degeneration as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Wet Macular Degeneration Revenue in 2024

Figure 19. North America Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Wet Macular Degeneration Market Share by Country (2020-2031)

Figure 21. United States Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Wet Macular Degeneration Market Share by Country (2020-2031)

Figure 25. Germany Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Wet Macular Degeneration Market Share by Region (2020-2031)

Figure 33. China Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Wet Macular Degeneration Market Share by Country (2020-2031)

Figure 41. Mexico Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Wet Macular Degeneration Market Share by Country (2020-2031)

Figure 45. Turkey Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Wet Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Pfizer Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 49. F. Hoffmann-La Roche AG Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 50. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 51. Novartis AG Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 52. Bausch Health Companies Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 53. Apellis Pharmaceuticals Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 54. GlaxoSmithKline plc Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 55. Ophthotech Corporation Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 56. Gilead Sciences, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 57. Alcon Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 58. Genzyme Corporation Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 59. Boehringer Ingelheim GmbH Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 60. EyeGate Pharmaceuticals, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 61. EyeCyte, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 62. PanOptica Inc Revenue Growth Rate in Wet Macular Degeneration Business (2020-2025)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Ophthalmology for Age related Macular Degeneration Diseases Market Research Report 2024

Global Retinal Disorders Treatment Market Research Report 2024

Retinal Degenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Macular Edema and Macular Degeneration Market Research Report 2025

Retinal Degenerative Disease Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Macular Degeneration Drug Pipeline Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Juvenile Macular Degeneration Treatment Market Research Report 2024

Global Macular Degeneration AMD and Other Retinal Diseases Market Research Report 2024

Global Macular Degeneration Treatment Market Research Report 2024

Global Eye Disorders Treatments Market Research Report 2024

Global Retinal Disease Therapeutics Market Research Report 2024

Global Digital Retinal Imaging System Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions